Transduction-ready viral particles

Amsbio offers a comprehensive range of pre-made lentiviral particles for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo.

Lentiviral particles provide long-term, stable expression of genes, making them ideal for stable cell line engineering, CRISPR applications, and therapeutic gene transfer.

Key advantages of Amsbio lentiviral particles include their ease of use, high titer, purity, and safety features. These pre-made lentiviral particles come ready-to-use, eliminating the need for transfection reagents and saving up to 4 weeks of work. The high-titer formulation of these particles (>1×107 IFU / mL) ensures high transduction efficiency for both adherent and suspension cells. Using proprietary third-generation, self-inactivating (SIN) vectors, Amsbio lentiviral particles are safe to use requiring only BSL-2 containment.

These advantages make Amsbio a strong choice for applications in gene knockdown/overexpression, CAR-T cell manufacturing, and in vivo studies. Drawing upon decades of experience and expertise – Amsbio can offer top quality pre-made lentiviral particles ranging from research-grade to GMP-grade for clinical applications.

In a new published study – US researchers describe using lentivirus supplied by Amsbio to help investigate the impact of the RNA binding protein (HuR) on CC-chemokine ligand 2 (CCL2) expression. This pioneering study identifies the molecular mechanism behind why certain individuals produce more CCL2, a protein linked to chronic inflammatory diseases like HIV-associated neurocognitive disorder and atherosclerosis. To read the study in full please visit https://elifesciences.org/articles/93108.

For further information on pre-made lentiviral particles please visit https://www.amsbio.com/products/cells-cell-culture/viral-delivery/lentiviral-particles or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Previous articleField-Ready, Science-Smart: Training the Next Generation of Pharma Reps